

The biological plausibility of the intervention should be discussed. The reduction in infectious diseases by IGC may reflect the deleterious effects of hyperglycemia on macrophage or neutrophil function or insulin-induced protective effects on mucosal and skin barriers.^{24–27} The improvement of innate immunity could be quite important, especially during the period of granulocytopenia after allogeneic HSCT. The protection of mucosal tissues could reduce bacterial translocation, which might lead to a reduced incidence of sepsis.

In conclusion, our results suggest that prospective IGC reduced the incidences of infectious diseases and organ dysfunction after allogeneic HSCT. To confirm these findings, a larger, prospective randomized-controlled trial is warranted.

Acknowledgements

We thank the medical, nursing, data processing, laboratory and clinical staffs at the National Cancer Center Hospital for their important contributions to this study through dedicated care of the patients. We are indebted to Y Iisaka for assisting with data collection. We also thank S Saito for helping to prepare the article. This study was supported in part by grants from the Ministry of Health, Labor and Welfare, Japan.

References

- 1 Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M *et al*. Intensive insulin therapy in the critically ill patients. *N Engl J Med* 2001; **345**: 1359–1367.
- 2 Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I *et al*. Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006; **354**: 449–461.
- 3 Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M *et al*. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycemic control. *Crit Care Med* 2003; **31**: 359–366.
- 4 Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc* 2003; **78**: 1471–1478.
- 5 Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. *Mayo Clin Proc* 2004; **79**: 992–1000.
- 6 Vogelzang M, Nijboer JM, van der Horst IC, Zijlstra F, ten Duis HJ, Nijsten MW. Hyperglycemia has a stronger relation with outcome in trauma patients than in other critically ill patients. *J Trauma* 2006; **60**: 873–877.
- 7 Ingels C, Debaveye Y, Milants I, Buelens E, Peeraer A, Devriendt Y *et al*. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. *Eur Heart J* 2006; **27**: 2716–2724.
- 8 Jeschke MG, Klein D, Bolder U, Einspanier R. Insulin attenuates the systemic inflammatory response in endotoxemic rats. *Endocrinology* 2004; **145**: 4084–4093.
- 9 Brix-Christensen V, Andersen SK, Andersen R, Mengel A, Dyhr T, Andersen NT *et al*. Acute hyperinsulinemia restrains endotoxin-induced systemic inflammatory response: an experimental study in a porcine model. *Anesthesiology* 2004; **100**: 861–870.
- 10 Sheean PM, Freels SA, Helton WS, Braunschweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2006; **12**: 656–664.
- 11 Sheean PM, Braunschweig C, Rich E. The incidence of hyperglycemia in hematopoietic stem cell transplant recipients receiving total parenteral nutrition: a pilot study. *J Am Diet Assoc* 2004; **104**: 1352–1360.
- 12 Fietsam Jr R, Bassett J, Glover JL. Complications of coronary artery surgery in diabetic patients. *Am Surg* 1991; **57**: 551–557.
- 13 Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidney. *J Invest Med* 1997; **45**: 50–56.
- 14 Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. *Lancet* 2005; **365**: 53–59.
- 15 Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S *et al*. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. *Transplantation* 2007; **84**: 814–820.
- 16 Saito AM, Kami M, Mori SI, Kanda Y, Suzuki R, Mineishi S *et al*. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan. *Am J Hematol* 2007; **82**: 873–880.
- 17 Fuji S, Kim S, Fukuda T, Kamiya S, Kuwahara S, Takaue Y. Positive impact of maintaining minimal caloric intake above 1.0 × basal energy expenditure on nutritional status of patients undergoing allogeneic hematopoietic stem cell transplantation. *Am J Hematol* 2008; **84**: 63–64.
- 18 Muscaritoli M, Grieco G, Capria S, Iori AP, Rossi Fanelli F. Nutritional and metabolic support in patients undergoing bone marrow transplantation. *Am J Clin Nutr* 2002; **75**: 183–190.
- 19 Fuji S, Kim SW, Fukuda T, Mori S, Yamasaki S, Morita-Hoshi Y *et al*. Pre-engraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and non-relapse mortality after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2008; **14**: 510–517.
- 20 Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hovs J *et al*. 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant* 1995; **15**: 825–828.
- 21 Ali NA, O'Brien Jr JM, Dungan K, Phillips G, Marsh CB, Lemeshow S *et al*. Glucose variability and mortality in patients with sepsis. *Crit Care Med* 2008; **36**: 2316–2321.
- 22 Van Cromphaut S, Wilmer A, Van den Berghe G. Management of sepsis. *N Engl J Med* 2007; **356**: 1179–1181.
- 23 Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. *Crit Care Med* 2007; **35**: 2262–2267.
- 24 Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. *Am J Med* 1982; **72**: 439–450.
- 25 Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). *FEMS Immunol Med Microbiol* 1999; **26**: 259–265.
- 26 Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. *Anesth Analg* 1999; **88**: 1011–1016.
- 27 Losser MR, Bernard C, Beaudeau JL, Pison C, Payen D. Glucose modulates hemodynamic, metabolic, and inflammatory responses to lipopolysaccharide in rabbits. *J Appl Physiol* 1997; **83**: 1566–1574.

LETTER TO THE EDITOR

Decreased insulin secretion in patients receiving tacrolimus as GVHD prophylaxis after allogeneic hematopoietic SCT

Bone Marrow Transplantation advance online publication, 3 August 2009; doi:10.1038/bmt.2009.154

As it has been reported that hyperglycemia is associated with a higher risk of non-relapse mortality after allogeneic hematopoietic SCT (HSCT), the efficient control of hyperglycemia has become an important consideration for safer HSCT.^{1–3} A characteristic feature of this field is the use of calcineurin inhibitors, including tacrolimus (TAC), which may cause hyperglycemia as suggested in organ transplant settings, possibly by decreasing insulin secretion.⁴ To evaluate this possibility, we serially monitored fasting glucose levels and serum immunoreactive insulin, and calculated homeostasis model assessment (HOMA)-IR and HOMA- β with the HOMA model⁵ as recommended by Wallace *et al.*⁶ HOMA-IR reflects insulin resistance and HOMA- β reflects the insulin secretion status.⁵ If HOMA-IR increased after the administration of allogeneic HSCT, drugs that reduce insulin resistance, such as metformin or pioglitazone, might theoretically be effective. In contrast, if HOMA- β decreased, drugs that increase insulin secretion, such as glucagon-like peptide-1 analog or sulfonylureas, might be effective. The data from this study may help us to better understand how we should control glucose levels after HSCT.

Data obtained from 43 adult patients who received allogeneic HSCT from October 2006 to December 2007 were included in the analysis. The median age of the patients was 48 years (range: 19–66 years). When patients were not receiving s.c. long-acting insulin, systemic

corticosteroid or parenteral nutrition, blood samples were obtained 1–2 months after HSCT. GVHD prophylaxis was started using CsA-based ($n=13$) or TAC-based regimens ($n=30$), with an additional short course of MTX in 35 patients. At the time of subsequent blood sampling, 15 patients were receiving CsA and 28 patients were receiving TAC, with no significant difference in various factors including age, gender, disease and intensity of the conditioning regimen (conventional vs reduced intensity), except that the TAC group included more HSCT with unrelated BM than the CsA group (89 vs 27%, respectively). The results regarding fasting glucose level, immunoreactive insulin and the HOMA model are summarized in Table 1.

We found that HOMA- β was significantly reduced in the TAC group compared with that in the CsA group, which was consistent with earlier studies in an organ transplant setting.⁴ Clinically, it has been reported that GVHD prophylaxis with TAC is generally associated with a reduced incidence of acute GVHD compared with CsA. In contrast, hyperglycemia was associated with a higher risk of non-relapse mortality after allogeneic HSCT.^{1,3} In our earlier study, patients with severe hyperglycemia had a significantly higher incidence of acute GVHD compared with normoglycemic patients.³ Therefore, it is possible that hyperglycemia related to the use of TAC could offset the potential benefit of TAC, and drugs that increase insulin secretion, including the glucagon-like peptide-1 analog, may reverse the suppression of the insulin level.⁷ Whether intensive glucose control could reduce the risk of acute

Table 1 Pretransplant and posttransplant glycaemic status

Variable	N (%) / Median (range)		P	P
	Tacrolimus (n = 28)	CsA (n = 15)		
Fasting glucose level (mg per 100 ml)				
Pretransplant	87 (80–129)	89 (79–154)	P = 0.08	P = 0.55
Posttransplant	95 (79–129)	91 (80–116)		
Immunoreactive insulin level (μU/ml)				
Pretransplant	6.1 (1.6–17.3)	6.6 (2.9–13.5)	P = 0.60	P = 0.25
Posttransplant	6.5 (1.5–18.0)	5.3 (2.4–10.1)		
HOMA-IR				
Pretransplant	1.4 (0.3–4.6)	1.4 (0.6–5.13)	P = 0.75	P = 0.40
Posttransplant	1.5 (0.3–4.2)	1.3 (0.5–2.2)		
HOMA-β				
Pretransplant	90.9 (30.3–193.7)	65.4 (38.7–160.0)	P = 0.04	P = 0.43
Posttransplant	69.9 (15.8–202.5)	61.7 (28.5–180.0)		

Abbreviations: HOMA = homeostasis model assessment; IR = insulin resistance.

GVHD in patients using TAC should be evaluated by prospective randomized control trials.

In conclusion, this is the first study to assess the change in the glycemic status with the HOMA model in patients undergoing HSCT with CsA or TAC. We showed that GVHD prophylaxis with TAC was associated with decreased insulin secretion and a resultant tendency for hyperglycemia. It is possible that measures to keep insulin and glucose levels within their respective normal ranges are effective for reducing morbidity and mortality after HSCT.

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements

This study was supported in part by grants from the Ministry of Health, Labor and Welfare, Japan, and the Advanced Clinical Research Organization.

S Fuji¹, S-W Kim¹, S Mori¹, K Furuta², R Tanosaki¹,
Y Heike¹, Y Takaue¹ and T Fukuda¹

¹Division of Stem Cell Transplantation, National Cancer
Center Hospital, Tokyo, Japan and

²Division of Laboratory Medicine, National Cancer Center
Hospital, Tokyo, Japan

E-mail: tafukuda@ncc.go.jp

References

- 1 Hammer MJ, Casper C, Gooley TA, O'Donnell PV, Boeckh M, Hirsch IB. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. *Biol Blood Marrow Transplant* 2009; **15**: 344–351.
- 2 Fuji S, Kim SW, Mori S, Kamiya S, Yoshimura K, Yokoyama H *et al*. Intensive glucose control after allogeneic hematopoietic stem cell transplantation: a retrospective matched-cohort study. *Bone Marrow Transplant* 19 January 2009 [e-pub ahead of print].
- 3 Fuji S, Kim SW, Mori S, Fukuda T, Kamiya S, Yamasaki S *et al*. Hyperglycemia during the neutropenic period is associated with a poor outcome in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation. *Transplantation* 2007; **84**: 814–820.
- 4 Pham PT, Pham PC, Lipshutz GS, Wilkinson AH. New onset diabetes mellitus after solid organ transplantation. *Endocrinol Metab Clin North Am* 2007; **36**: 873–890.
- 5 Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 1985; **28**: 412–419.
- 6 Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care* 2004; **27**: 1487–1495.
- 7 Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I *et al*. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet* 2009; **373**: 473–481.

Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens

S. Yamasaki, Y. Heike, S. Mori, T. Fukuda, D. Maruyama, R. Kato, E. Usui, K. Koido, S. Kim, R. Tanosaki, K. Tobinai, T. Teshima, Y. Takauae.

Infectious complications in chronic graft-versus-host disease: a retrospective study of 145 recipients of allogeneic hematopoietic stem cell transplantation with reduced- and conventional-intensity conditioning regimens.

Transpl Infect Dis 2008; 10: 252–259. All rights reserved

Abstract: To assess infectious complications associated with chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced- and conventional-intensity conditioning regimens (RIC, $n = 91$; CIC, $n = 54$, respectively), we retrospectively analyzed data from 145 consecutive patients with cGVHD after allogeneic HSCT from a human leukocyte antigen-matched related or unrelated donor. In the present retrospective analysis, 57% (83/145) of patients with cGVHD developed infections, with a mortality rate of 27% (22/83). The incidences of bacteremia ($n = 28$), central venous catheter-related infections ($n = 11$), bacterial pneumonia ($n = 4$), invasive aspergillosis ($n = 7$), and adenoviral hemorrhagic cystitis ($n = 8$) were significantly higher in patients with prednisolone dose ≥ 1 mg/kg at the time of diagnosis of cGVHD. The present results suggest that infections associated with cGVHD, especially after high-dose prednisolone, are predictive of poor outcome regardless of whether the patient received RIC or CIC.

S. Yamasaki¹, Y. Heike¹, S. Mori¹, T. Fukuda¹, D. Maruyama¹, R. Kato¹, E. Usui¹, K. Koido¹, S. Kim¹, R. Tanosaki¹, K. Tobinai¹, T. Teshima², Y. Takauae¹

¹Division of Hematology/Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan, ²Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan

Key words: infectious complication; chronic graft-versus-host disease; allogeneic hematopoietic stem cell transplantation; reduced-intensity conditioning; HLA-matched donor

Correspondence to:

Yuji Heike, MD, PhD, Division of Hematology/Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Tel: + 81 3 3542 2511

Fax: + 81 3 3545 3567

E-mail: yheike@ncc.go.jp

Received 26 May 2007, revised 11 July, 23 July, 4 September 2007, accepted for publication 12 September 2007

DOI: 10.1111/j.1399-3062.2007.00291.x

Transpl Infect Dis 2008; 10: 252–259

Infectious complications contribute to morbidity and mortality following allogeneic hematopoietic stem cell transplantation (HSCT). Well-known factors affecting susceptibility to infections include donor type, conditioning regimen, development of graft-versus-host disease (GVHD), and environmental factors. Reduced-intensity conditioning (RIC) regimens are thought to lower the risk of infections because they involve relatively little damage to vital organs (1). However, our experience indicates that with both RIC and conventional-intensity conditioning (CIC) regimens, the incidence of bacterial infections during neutropenia and *Aspergillus* infections is high after allogeneic HSCT (2, 3). Thus, it appears that RIC alone is not sufficient to improve the safety of allogeneic HSCT.

GVHD and the treatment of GVHD with immunosuppressive drugs are also well-known predominant risk

factors for the development of opportunistic infections (4–6). In the case of acute GVHD, inpatients can be given comprehensive prophylaxis, including environmental control, to prevent infections over the short term. In contrast, chronic GVHD (cGVHD) is most often a late complication of allogeneic HSCT, and is usually treated on an outpatient basis. Consequently, the resources that can be used to control infections in patients with cGVHD are limited, and prophylaxis should be considered as a long-term approach, taking into account the safety and emergence of drug-resistant pathogens. In Japanese patients, the incidence of cGVHD after allogeneic HSCT is reportedly as high as 50%, with 20% of those who develop cGVHD contracting concurrent infections (7). At present, more transplantation procedures are being performed with peripheral blood stem cell (PBSC) products, in older patients, and with

unrelated donors. The available evidence suggests that all of these factors would result in greater numbers of patients with cGVHD. Thus, management of cGVHD is one of the greatest challenges to physicians practicing HSCT.

In the present study, we evaluated infectious complications associated with cGVHD in patients who received an RIC or a CIC regimen before undergoing PBSC transplantation (PBSCT) from a human leukocyte antigen (HLA)-matched relative (related PBSCT) or bone marrow transplantation (BMT) from an HLA-matched unrelated volunteer (unrelated BMT).

Patients and methods

Patient characteristics

We retrospectively analyzed data from 145 consecutive adult patients with hematologic malignancies who had received allogeneic HSCT with an RIC ($n = 91$) or CIC ($n = 54$) regimen between January 2000 and December 2004 at our institution. All of these 145 patients had sustained engraftment, had survived for >100 days following transplantation, and had developed cGVHD. The following types of patients were excluded: patients who suffered from disease progression before the development of cGVHD and received donor lymphocyte infusion, and patients with a history of previous allogeneic HSCT. Significant differences were observed between the RIC and CIC groups in terms of the age of the patients and donors, the gender of the patients, diagnosis, disease risk (8), time from diagnosis to transplantation, donor type and source of stem cells, and GVHD prophylaxis. The patient characteristics are summarized in Table 1. Typing for HLA-A, -B, and -DR antigens of the donor and recipient was performed using low-resolution DNA typing. The frequency with which allogeneic PBSCT is performed in Japan has been increasing since it became eligible for reimbursement from health insurance organizations in the year 2000, and our banking system only approves donation of bone marrow. The clinical characteristics of cGVHD, including use of immunosuppressive drugs at diagnosis and initial treatment, are summarized in Table 2. The present study was approved by the Ethics Committee of our institution, and all 145 subjects provided informed consent.

Conditioning regimen and supportive care

The CIC regimen consisted of cyclophosphamide (CY, 120 mg/kg), in combination with either 12 Gy total-body irradiation (TBI, $n = 25$) or busulfan (BU, 16 mg/kg; $n = 29$). The RIC regimen consisted of BU (8 mg/kg) in combination with either fludarabine (Flu, 180 mg/m²; $n = 70$) or 2-chlorodeoxyadenosine (2-CdA, 0.66 mg/kg; $n = 21$); 14

patients received either anti-thymocyte globulin (ATG, 5–10 mg/kg; $n = 6$) or 4 Gy TBI ($n = 8$). All patients received cyclosporine (CSP, 3 mg/kg/day; $n = 137$) or tacrolimus (TAC, 0.03 mg/kg/day; $n = 8$), with ($n = 78$) or without ($n = 67$) short courses of methotrexate (MTX; related PBSCT, 10 mg/m² on day 1, and 7 mg/m² on days 3 and 6; unrelated BMT, 10 mg/m² on days 3, 6, and 11) as GVHD prophylaxis. All patients received prophylactic ciprofloxacin (200 mg orally 3 times daily) for prevention of infections until neutrophil recovery. Trimethoprim-sulfamethoxazole (80 mg of trimethoprim once daily) was administered for the prevention of *Pneumocystis* pneumonia and encapsulated bacterial infection, from the first day of the conditioning regimen until day 3, and from day +30 until 6 months after transplantation, or for prolonged periods in patients with cGVHD. Patients also received oral or intravenous fluconazole (100 mg once daily) for prevention of infection by *Candida* species, and low-dose acyclovir (600 mg until engraftment, and then 100 mg/day orally), starting at the same time as the conditioning regimens and continuing until cessation of administration of immunosuppressive drugs (9). Cytomegalovirus (CMV) antigenemia was monitored weekly until cessation of the administration of immunosuppressive drugs. Testing for CMV antigenemia consisted of direct immunoperoxidase staining of leukocytes with a peroxidase-labeled monoclonal antibody. Quantitative real-time polymerase chain reaction was not performed.

Definition of outcome

Patients with grades II–IV acute GVHD were treated with prednisolone (PSL) according to a standard regimen (10). Chronic GVHD was assessed and graded according to the standard criteria (11). The diagnosis and staging of cGVHD were also assessed according to the working report published by the National Institutes of Health Consensus Development Project (12). Relapse was defined either by morphologic evidence of the disease in the peripheral blood, marrow, or extramedullary sites, or by recurrence and persistence of pre-transplant chromosomal abnormalities in cytogenetic analysis of the marrow cells.

Infectious complications

A documented infection was defined as signs and symptoms associated with microbiological documentation of a pathogen from the site of infection. Culture-documented bacteremia, fungemia, or viremia was considered to be a definite infection, regardless of symptoms. On the other hand, clinical infection was defined as signs or symptoms consistent with an infection, but without microbiological confirmation. Central venous catheter (CVC)-related

Patient characteristics and transplant outcomes

	RIC (n = 91)	CIC (n = 54)	P
Median age of patients (range)	55 (26–68)	37 (18–53)	< 0.0001
Median age of donors (range)	50 (17–69)	34 (19–54)	< 0.0001
Male/female patient	57 ¹ /34	22/32	0.015
Female donor for male patient	19	10	0.83
Diagnosis AML (+ MDS)	27 (9)	17 (4)	0.0029
MDS	17	4	
CML	7	12	
ALL	1	8	
ML	36	13	
Others ²	3	0	
Disease risk group (standard/advanced) ³	14/77	21/33	0.0023
Median time interval ⁴ (range), (months)	19 (2–178)	10 (1–100)	0.014
KPS ⁵ ≤ 80%	10	5	0.41
HCT-SCI ⁶ ≥ 2	13	7	0.99
Prior infectious complications	6	3	0.99
Prior autologous transplantation	5	2	0.99
Donor type and source of stem cells			
Related PBSC/Unrelated BM	82/9	34/20	0.0002
GVHD prophylaxis			
CSP or TAC alone/MTX with CSP or TAC	66/25	1/53	< 0.0001
Acute GVHD grade II/III/IV	24/23/3	18/8/2	0.072
Median onset day (range) of grades II–IV acute GVHD ⁷	39 (12–97)	32 (14–91)	0.48
Prior use of PSL for acute GVHD			
0.5–<1.0/1.0–<2.0/≥ 2.0 mg of PSL/kg	5/34/18	4/13/9	0.27
Relapse/progressive disease following cGVHD	16	10	0.99
Cause of death	30	20	0.27
Infection	15 ⁸	7 ⁸	
Chronic GVHD	9 ⁸	8 ⁸	
Lungs/gastrointestinal tract/MOF/Others ⁹	3/1/3/2	3/3/2/0	
Others ¹⁰	3	6	
Progression	8	2	
Median follow-up (range), (months)	39 (5–73)	45 (15–79)	0.20

¹Number of patients, unless indicated otherwise.

²Others = myelofibrosis (n = 1), chronic lymphocytic leukemia (n = 1), and multiple myeloma (n = 1).

³Patients who were considered standard risk with a diagnosis of AML + MDS or AML, or ALL in first complete remission, CML in first chronic phase, or untreated refractory anemia in MDS. All other conditions were considered to indicate advanced risk.

⁴Time from diagnosis to transplantation.

⁵KPS was evaluated before the start of the conditioning regimen, and was graded according to Karnofsky performance status score.

⁶HCT-SCI was evaluated before the start of the conditioning regimen, and was graded according to hematopoietic cell transplantation-specific comorbidity index (ref. 8).

⁷Time from occurrence of grades II–IV acute GVHD to transplantation.

⁸Total number of patients differs because 8 patients (RIC, 5; CIC, 3) died of both infection and chronic GVHD.

⁹Others = renal (n = 1) and liver (n = 1).

¹⁰Others = RIC: cerebral infarction (n = 1), secondary hepatocellular carcinoma (n = 1), infection following secondary allogeneic cord blood stem cell transplantation; CIC: acute myocardial infarction (n = 1), cerebral infarction (n = 1), drug-induced interstitial pneumonia (n = 1), infection following chemotherapy (n = 1), and suicide (n = 2).

RIC, reduced-intensity regimen; CIC, conventional-intensity regimen; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CML, chronic myeloid leukemia; ALL, acute lymphoblastic leukemia; ML, malignant lymphoma; PBSC, peripheral blood stem cell; BM, bone marrow; CSP, cyclosporine; TAC, tacrolimus; MTX, methotrexate; GVHD, graft-versus-host disease; PSL, prednisolone; cGVHD, chronic graft-versus-host disease; MOF, multiple organ failure.

Table 1

Clinical characteristics of cGVHD

	RIC	CIC	P
Median onset day (range) ¹	100 (79–479)	109 (93–348)	0.51
Limited/extensive	5/86	1/53	0.41
De novo/quiescent/progressive	27/38/26	24/9/21	0.16
KPS score 1/2/3	61/16/8	46/2/2	0.045
Skin score 1/2/3	27/33/8	17/12/3	0.15
Mouth score 1/2/3	40/29/3	23/9/1	0.87
Eyes score 1/2/3	30/14/7	15/9/1	0.38
Gastrointestinal tract score 1/2/3	28/4/12	19/1/7	0.84
Liver score 1/2/3	7/23/44	6/13/24	0.89
Lungs score 1/2/3	6/8/4	8/7/1	0.26
Joints and fascia score 1/2/3	13/2/0	8/5/1	0.13
Genital tract score 1/2/3	1/0/0	0/0/0	0.99
Eosinophilia > 0.5 × 10 ⁹ /L	30	22	0.37
Platelets < 100 × 10 ⁹ /L	26	20	0.36
Others ²	5	2	0.39
Immunosuppressive drugs at diagnosis of cGVHD			
CSA/TAC	66/3	37/3	0.76
<0.5/0.5–<1.0/1.0–<2.0/ ≥ 2.0 mg of PSL/kg	17/9/11/2	9/2/3/1	0.57
Initial treatment for cGVHD			
Addition or increased dose of CSA/TAC	69/7	41/4	0.99
<0.5/0.5–<1.0/1.0–<2.0/ ≥ 2.0 mg of PSL/kg	18/14/15/4	10/7/6/2	0.74
Median follow-up from diagnosis of cGVHD (range) (months)	39 (5–73)	45 (15–79)	0.26

¹Time from occurrence of cGVHD to transplantation.
²Others = pleural effusion (n = 4), pericardial effusion (n = 3), ascites (n = 3), and polymyositis (n = 1).
RIC, reduced-intensity regimen; CIC, conventional-intensity regimen; cGVHD, chronic graft-versus-host disease; KPS, Karnofsky performance status; CSP, cyclosporine; TAC, tacrolimus; PSL, prednisolone.

Table 2

infections consisted of exit site infections without bacteremia. Bacterial pneumonia was included in the category of definite infections, and was diagnosed by chest x-ray examination or computed tomography (CT) and identification of a bacterial pathogen on culture of sputum, bronchoalveolar lavage fluid, pleural fluid, or blood specimen. Fungal infections, including proven or probable invasive fungal infections, were diagnosed by identification of a fungal pathogen on culture or *Aspergillus* antigen and CT examination according to consensus criteria (13). Pneumonia of unknown origin was included in the category of undefined pneumonias, which were diagnosed by chest x-ray and/or CT. There was no significant difference in CMV serostatus between the RIC and CIC groups (data not shown). A polymicrobial infection of 1 organ or several adjacent organs was considered to be a single infection. Death associated with a documented infection was defined as the death of a patient with findings consistent with an

infection, or as detection of the pathogen in an autopsy specimen.

Statistical analysis

Comparisons of variables were performed using the 2-tailed Fisher exact test or the χ^2 test. Continuous variables were compared by the Mann-Whitney *U*-test. All *P*-values were 2-sided, and the type I error rate was fixed at *P* < 0.05.

Results

Transplant outcomes

The transplant outcomes are summarized in Table 1. Twenty-two patients (RIC, *n* = 15; CIC, *n* = 7) died of infections, of whom 8 patients (RIC, *n* = 5; CIC, *n* = 3) died of

both infections and chronic GVHD, with cGVHD at a median follow up of 40 months from transplantation (RIC, 39 vs. CIC, 45 months). The median onset of cGVHD was 112 days (RIC, 100 vs. CIC, 109 days), and 47 patients (RIC, $n = 26$; CIC, $n = 21$) developed progressive-type cGVHD at a median follow up of 32 months from diagnosis of cGVHD (RIC, 39 vs. CIC, 45 months). The severity of the Karnofsky performance status (KPS) score was significantly greater in the RIC group ($P = 0.045$).

Infectious complications

A total of 134 infectious episodes occurred in 83 patients (RIC, 51 vs. CIC, 32; $P = 0.73$), as shown in Table 3. Of these, 28 patients (RIC, 18 vs. CIC 10; $P = 0.83$) developed bacteremia, the causative organisms (43 positive cultures) of which are summarized in Table 4. Gram-positive bacteremia (27 positive cultures) was more common than gram-negative bacteremia (16 positive cultures). The bacteremia was caused by 2, 3, and 4 types of organisms in 4, 4, and 1 patient, respectively. The incidence of bacteremia was significantly higher in patients with the following factors:

cGVHD including progressive types ($n = 15$, $P = 0.0027$), a KPS score ≥ 2 ($n = 11$, $P = 0.0062$) and a gastrointestinal (GI) score ≥ 2 ($n = 13$, $P < 0.0001$); PSL dose ≥ 1 mg/kg at the time of diagnosis ($n = 9$, $P = 0.00090$) and for the initial treatment of cGVHD ($n = 11$, $P = 0.0050$). CVC-related infections ($n = 11$) were caused by *Staphylococcus epidermidis* ($n = 4$), *Staphylococcus* species ($n = 2$), *Stenotrophomonas maltophilia* ($n = 2$), *Acinetobacter iwoffii* ($n = 1$), *Corynebacterium* species ($n = 1$), or methicillin-resistant *Staphylococcus aureus* (MRSA, $n = 1$). The incidence of CVC-related infections was significantly higher in patients with PSL dose ≥ 1 mg/kg at the time of diagnosis of cGVHD ($n = 4$, $P = 0.026$). Bacterial pneumonia was observed in 4 patients, and the isolated organisms were as follows: *Pseudomonas aeruginosa* ($n = 1$), *Hemophilus influenzae* ($n = 1$), *S. epidermidis* ($n = 1$), and *Staphylococcus* species ($n = 1$). The incidence of bacterial pneumonia ($n = 4$) was significantly higher in patients with PSL dose ≥ 1 mg/kg at the time of diagnosis ($n = 3$, $P = 0.0051$) and for the initial treatment of cGVHD ($n = 3$, $P = 0.021$). Invasive aspergillosis (IA) and *Candida* infections developed in 7 and 3 patients, respectively. All patients with IA had been given ≥ 0.5 mg of PSL/kg at the time of diagnosis of cGVHD. The incidence

Infectious complications associated with cGVHD

	Total (median onset, range, days)	RIC	CIC	P
Bacterial infections				
Bacteremia	28 (175, 104–1629)	18 (5) ¹	10 (2)	0.83
CVC-related	11 (123, 101–1774)	5 (0)	6 (0)	0.33
Pneumonia	4 (311, 101–1045)	3 (2)	1 (1)	0.99
Others ²	16 (302, 102–1065)	7 (4)	9 (2)	0.11
Fungal infections				
<i>Candida</i> infection	3 (128, 101–358)	1 (0)	2 (0)	0.56
Invasive aspergillosis	7 (181, 112–1232)	6 (0)	1 (0)	0.26
Viral infections				
Adenoviral hemorrhagic cystitis	8 (192, 111–538)	5 (0)	3 (0)	0.99
CMV colitis	1 (343)	0 (0)	1 (0)	0.37
Cutaneous VZV	18 (502, 106–1684)	12 (0)	6 (0)	0.80
Influenza	4 (483, 355–898)	1 (0)	3 (0)	0.15
Others ³	2 (133, 103–164)	1 (0)	1 (0)	0.99
CMV antigenemia	15 (140, 104–448)	11 (0)	4 (0)	0.42
Pneumoniae of unknown origin	32 (283, 101–1735)	18 (4)	14 (4)	0.41

¹Number of infectious episodes (number of deaths) is shown.

²Others = sepsis of unknown origin (4 episodes), dermatitis (3), hemorrhagic cystitis (2), otitis media (2), meningitis (2), cholecystitis (1), pseudomembranous enterocolitis (1), and urinary tract infection (1).

³Others = herpes simplex viral esophagitis (1 episode) and meningitis (1).

cGVHD, chronic graft-versus-host disease; RIC, reduced-intensity regimen; CIC, conventional-intensity regimen; CVC, central venous catheter; CMV, cytomegalovirus; VZV, varicella zoster virus.

Table 3

Bacteremia associated with cGVHD

	RIC (n = 18)	CIC (n = 10)
Gram-positive organisms	16 ¹	11
<i>Staphylococcus epidermidis</i>	7	2
<i>Streptococcus</i> species	2	3
<i>Enterococcus</i> species	3	0
<i>Staphylococcus</i> species	0	3
<i>Bacillus</i> species	0	1
<i>Corynebacterium</i> species	1	0
MRSA	0	1
Gram-positive cocci	3	1
Gram-negative organisms	10	6
<i>Bacteroides</i> species	3	2
<i>Pseudomonas aeruginosa</i>	2	2
<i>Klebsiella</i> species	2	0
<i>Enterobacter</i> species	0	1
<i>Escherichia coli</i>	0	1
Gram-negative rods	3	0

¹Number of positive cultures.
cGVHD, chronic graft-versus-host disease; RIC, reduced-intensity regimen; CIC, conventional-intensity regimen; MRSA, methicillin-resistant *Staphylococcus aureus*.

Table 4

of IA was significantly higher in patients with cGVHD including a GI score ≥ 2 ($n = 4$, $P = 0.015$), PSL dose ≥ 1 mg/kg at the time of diagnosis ($n = 4$, $P = 0.0037$), and for the initial treatment of cGVHD ($n = 7$, $P < 0.0001$). Eighteen patients developed cutaneous varicella zoster virus (VZV); all responded promptly to acyclovir. Eight patients developed adenoviral hemorrhagic cystitis (HC); 2 of these 8 patients developed continuously complicated lethal bacteremia. The incidence of adenoviral HC was significantly higher in patients with cGVHD including a KPS score ≥ 2 ($n = 5$, $P = 0.0071$) and a GI score ≥ 2 ($n = 4$, $P = 0.026$); PSL dose ≥ 1 mg/kg at the time of diagnosis ($n = 4$, $P = 0.0069$); and for the initial treatment of cGVHD ($n = 5$, $P = 0.0060$). *De novo* CMV antigenemia before or after development of cGVHD was observed in 62 and 15 patients, respectively. Sixteen and 8 patients, respectively, died of bacterial infections and pneumonias of unknown origin.

Discussion

In the present retrospective analysis, 57% (83/145) of patients with cGVHD developed infections, with a mortality rate of 27% (22/83). Although the limitations of this study

were the retrospective study design and the differences in baseline characteristics in both the RIC and CIC groups, these results illustrate the importance of establishing more effective management of infectious complications associated with cGVHD, which are predictive of poor outcome for both RIC and CIC regimens.

In patients with cGVHD, the major source of bacteremia was heterogeneous, gram-positive organisms such as *S. epidermidis* and *Streptococcus* species, which were more common than gram-negative organisms, and bacteremia caused by *Pseudomonas aeruginosa*, including multidrug-resistant *P. aeruginosa*, occurred only in patients with cGVHD involving a GI tract score ≥ 2 . Additionally, *Streptococcus pneumoniae* sepsis was a risk factor for non-relapse mortality, as reported previously (4), and pneumococcal vaccination of transplant recipients was found to be relatively ineffective in the presence of cGVHD. In other studies with RIC regimens, the incidence of bacteremia appeared to be significantly lower than in the present study, but this may be a result of the shorter follow-up periods in those studies (14, 15). Moreover, 29% (7/24) of the present patients with cGVHD involving a GI tract score ≥ 2 had received ≥ 2 mg of PSL/kg before developing cGVHD, and all 7 of these patients developed bacteremia. Although 50% (14/28) of patients with bacteremia received antibiotic

drugs and all 14 of these patients received intravenous immunoglobulin to maintain IgG levels at >400 mg/dL for prophylaxis of encapsulated bacteria and *Pneumocystis*, these results suggest that patients with cGVHD having a GI tract score ≥ 2 , especially after high-dose PSL, are more likely to develop bacteremia than patients with cGVHD not having a GI tract score ≥ 2 . This was probably due to colonization of the GI tract resulting from translocation into the bloodstream or disruption of the ecologic GI equilibrium involving GI bacterial overgrowth (e.g., use of antibiotic decontamination), increased permeability of the GI mucosal barrier (e.g., GVHD-induced mucosal damage), or deficiencies in the host immune defenses (e.g., use of immunosuppressive drugs). Thus, a review of strategies for prevention of bacteremia may lead to improvement of patient outcomes after allogeneic HSCT. That is, in patients with cGVHD having a GI tract score ≥ 2 , restrictions on the use of broad-spectrum antibiotics may help reduce GI bacterial overgrowth, including overgrowth by antibiotic-resistant organisms, resulting from failure of the GI barrier. In contrast, we recognize the difficulty in identifying bacteremia using culturing blood. Our patients were immunocompromised hosts who presented with undifferentiated fever; therefore, blood culture results were often delayed well into the course of empirical therapy. There is a need to develop suitable strategies for screening of bacteremia associated with cGVHD in patients who receive allogeneic HSCT with either RIC or CIC regimens.

Most of the present patients with cGVHD who developed *Candida* infection or IA received ≥ 0.5 mg of PSL/kg before developing cGVHD and the incidence of IA was significantly higher in patients with cGVHD having a GI score ≥ 2 , especially after high-dose PSL. The number of patients with fungal infections was small, but high-dose PSL may be effective for improving the prophylaxis for such infections. Furthermore, the duration of prophylaxis still remains unclear as randomized clinical trials have yet to be conducted.

All the present patients with adenoviral HC developed grades II–IV acute GVHD and received PSL for GVHD therapy, which differs considerably from what has been reported previously (16). The incidence of adenoviral HC was significantly higher in patients with cGVHD having a KPS score ≥ 2 , a GI score ≥ 2 , and high-dose PSL at the time of diagnosis and for the initial treatment of cGVHD. Although the present study was limited in its ability to detect risk factors for adenoviral HC, because of low patient numbers and lack of prospective investigation of viral infection, the present results suggest that patients who receive high-dose PSL before and after developing cGVHD should be frequently checked for abdominal and urinary symptoms, and that urinary tests should be regularly

performed during ongoing use of immunosuppressive drugs. In addition, we identified only 1 patient with cGVHD who suffered from CMV colitis, indicating that it is useful to monitor and treat CMV antigenemia intensively in patients receiving immunosuppressive drugs, especially before development of cGVHD. In contrast, 12% of the present patients with cGVHD developed cutaneous VZV with a median onset of 502 days (range, 106–1684), despite low-dose acyclovir prophylaxis during at least the first year after allogeneic HSCT. Nonetheless, there were no cases of breakthrough VZV infection. This suggests that low-dose acyclovir prophylaxis effectively prevented breakthrough VZV infection, but that reestablishment of antiviral therapy was needed to protect against cutaneous VZV in patients with cGVHD.

In summary, the present data indicate that infections associated with cGVHD, especially after high-dose PSL, are predictive of poor outcome, whether RIC or CIC is used. Accordingly, there is a need for clinical trials to develop new strategies for screening and prevention of infections associated with cGVHD in patients who receive allogeneic HSCT with either RIC or CIC regimens.

References

1. Perez-Simon JA, Diez-Campelo M, Martino R, et al. Influence of the intensity of the conditioning regimen on the characteristics of acute and chronic graft-versus-host disease after allogeneic transplantation. *Br J Haematol* 2005; 130: 394–403.
2. Hori A, Kami M, Kim SW, et al. Development of early neutropenic fever, with or without bacterial infection, is still a significant complication after reduced-intensity stem cell transplantation. *Biol Blood Marrow Transplant* 2004; 10: 65–72.
3. Kojima R, Tateishi U, Kami M, et al. Chest computed tomography of late invasive aspergillosis after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2005; 11: 506–511.
4. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. *Blood* 2000; 95: 3683–3686.
5. Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. *Clin Infect Dis* 2001; 33: 139–144.
6. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. *Clin Infect Dis* 2002; 34: 1098–1107.
7. Atsuta Y, Suzuki R, Yamamoto K, et al. Risk and prognostic factors for Japanese patients with chronic graft-versus-host disease after bone marrow transplantation. *Bone Marrow Transplant* 2006; 37: 289–296.
8. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. *Blood* 2005; 106: 2912–2929.
9. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2001; 28: 689–692.

10. Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. *Am J Hematol* 1981; 11: 1–9.
11. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. *Am J Med* 1980; 69: 204–217.
12. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant* 2005; 11: 945–956.
13. Ascioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: an international consensus. *Clin Infect Dis* 2002; 34: 7–14.
14. Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. *Biol Blood Marrow Transplant* 2002; 8: 512–520.
15. Busca A, Locatelli F, Barbui A, et al. Infectious complications following nonmyeloablative allogeneic hematopoietic stem cell transplantation. *Transpl Infect Dis* 2003; 5: 132–139.
16. El-Zimaity M, Saliba R, Chan K, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters. *Blood* 2004; 103: 4674–4680.

[Faint, illegible text, likely bleed-through from the reverse side of the page]

[Faint, illegible text, likely bleed-through from the reverse side of the page]

Impact of T Cell Chimerism on Clinical Outcome in 117 Patients Who Underwent Allogeneic Stem Cell Transplantation with a Busulfan-Containing Reduced-Intensity Conditioning Regimen

Bungo Saito, Takahiro Fukuda, Hiroki Yokoyama, Saiko Kurosawa, Toshihiro Takahashi, Shigeo Fuji, Noriko Takahashi, Kinuko Tajima, Sung-Won Kim, Shin-ichiro Mori, Ryuji Tanosaki, Yoichi Takaue, Yuji Heike

Within the concept of reduced-intensity stem cell transplantation (RIST) there is a wide range of different regimens used, and little information is available on the clinical impact of chimerism status in patients conditioned with a busulfan-containing regimen. Therefore, we retrospectively reviewed lineage-specific chimerism and the subsequent clinical outcome in 117 patients (median age, 55 years; range: 29-68) who underwent busulfan-containing RIST. The conditioning regimen consisted of busulfan (oral 8 mg/kg or i.v. 6.4 mg/kg) and fludarabine (180 mg/m², n = 64) or cladribine (0.66 mg/kg, n = 53), with or without 2-4 Gy total-body irradiation (TBI) (n = 26) or antihuman T-lymphocyte immunoglobulin (ATG; 5-10 mg/kg; n = 31). Chimerism was evaluated with peripheral blood samples taken on days 30, 60, and 90 after transplantation by polymerase chain reaction (PCR)-based amplification of polymorphic short tandem repeat regions. The median follow-up of surviving patients was 1039 days (153-2535). The percent donor-chimerism was significantly higher in granulocyte than T cell fraction throughout the entire course, and the median (mean) values were, respectively, 100% (96%) versus 95% (83%), 100% (98%) versus 100% (89%), and 100% (98%) versus 100% (91%) at days 30, 60, and 90 after RIST. In a multivariate analysis, having received <2 types of chemotherapy regimens before RIST was the only factor that was significantly associated with low donor T cell chimerism (<60%) at day 30 (hazard ratio [HR]: 6.1; 95% confidence interval [CI], 2.1-18.4; *P* < .01). The median percentage of donor T cell chimerism at day 30 was 9% (0%-63%) in 5 patients who experienced graft failure, which was significantly lower than that (97%; 15%-100%) in the rest of the patients (*P* < .01). No correlation was found between the kinetics of T cell chimerism and the occurrence of acute or chronic GVHD (aGVHD, cGVHD). The stem cell source and the addition of TBI or ATG were not associated with the degree of T cell chimerism, overall survival (OS) or event-free survival (EFS). In a Cox proportional hazard model, low donor T cell chimerism of <60% at day 30 was associated with both poor OS (HR: 2.2; 95% CI, 1.1-4.5; *P* = .02) and EFS (HR: 2.0; 95% CI, 1.1-3.8; *P* = .02). In conclusion, we found that 43% of the patients retained mixed donor T cell chimerism (<90% donor) at day 30, whereas 92% achieved complete chimerism in granulocyte fraction. Low donor T cell chimerism of <60% at day 30 may predict a poor outcome, and a prospective study to examine the value of early intervention based on chimerism data is warranted.

Biol Blood Marrow Transplant 14: 1148-1155 (2008) © 2008 American Society for Blood and Marrow Transplantation

KEY WORDS: Reduced-intensity stem cell transplantation, Chimerism, Busulfan

From the Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan

Financial disclosure: See Acknowledgments on page 1154.

Correspondence and reprint requests: Takahiro Fukuda, MD, PhD, Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan (e-mail: tafukuda@ncc.go.jp).

Received March 10, 2008; accepted July 20, 2008

1083-8791/08/1410-0001\$34.00/0

doi:10.1016/j.bbmt.2008.07.013

INTRODUCTION

Hematopoietic stem cell transplantation (HSCT) with a reduced-intensity conditioning (RIC) regimen has been increasingly used in patients with hematologic diseases who cannot be candidates for conventional HSCT because of age, medical comorbidities, or prior failed myeloablative SCT. Many different RIC regimens are currently in use, but most of them

incorporate fludarabine (Flu) as a background agent in combination with other drugs including cyclophosphamide (Cy) [1], melphalan (Mel) [2], busulfan [2,3], low-dose total body irradiation (TBI) [4], antithymocyte globulin (ATG) [3], and alemtuzumab [5].

RIC regimens have been investigated in the hope of reducing toxicity, whereas their engraftment potential and antileukemia effect rely mainly on the expansion of donor-derived cells and subsequent immune-mediated graft-versus-leukemia (GVL) effects [6,7]. In this setting, lineage-specific chimerism analysis to assess the origin of lymphohematopoietic cells becomes particularly important for identifying patients at risk for graft failure/rejection, graft-versus-host disease (GVHD), and relapse or progressive disease (PD) [4,8,9]. Because the posttransplantation chimerism status is based on a fine balance between the cytotoxicity or immunosuppressive potential of the regimen used and the recipient's reserve immunocompetence, each RIC regimen should be evaluated individually for chimerism kinetics [1,4,10-13].

Compared with a regimen that includes Flu and Me, it has been reported that the combination of Flu and i.v. Bu was associated with improved survival in patients transplanted in remission, which was more frequently associated with mixed chimerism [2]. However, very little information is currently available on the clinical impact of lineage-specific chimerism status in patients who are conditioned with a Bu-containing RIC regimen. Therefore, we examined the correlation between specific patterns of lineage-specific chimerism and subsequent clinical outcomes.

PATIENTS AND METHODS

Patients and Transplantation Procedures

We retrospectively reviewed the medical records of 117 patients who had various hematologic malignancies and underwent allogeneic HSCT with Bu-containing RIC at our hospital from January 2000 to December 2006. The reasons for selecting RIC regimens included older patient age, medical comorbidities, and prior failed myeloablative SCT. The patients' characteristics are summarized in Table 1. The median age of the patients was 52 years (range: 29-68 years), and the hematologic malignancy included acute myelogenous leukemia (AML) (n = 23), AML evolving from a myelodysplastic syndrome (MDS) (n = 16), acute lymphoblastic leukemia (ALL) (n = 5), malignant lymphoma (n = 44), MDS (n = 16), chronic myelogenous leukemia (CML) (n = 9), chronic lymphocytic leukemia (CLL) (n = 1), multiple myeloma (MM) (n = 1), and atypical CML (n = 2).

The conditioning regimen consisted of Bu (oral 8 mg/kg or i.v. 6.4 mg/kg) and Flu (180 mg/m², n = 64) or cladribine (0.66 mg/kg, n = 53), with or without

Table 1. Association between patients characteristics and donor T-cell chimerism at day 30

Characteristics	Total (n=117)	T cell chimerism at day 30	
		<60% (n=18)	≥60% (n=99)
Patient age, years			
Median (range)	55 (29-68)	57 (35-66)	54 (29-68)
<55	56 (48%)	6 (33%)	50 (51%)
≥55	61 (52%)	12 (67%)	49 (49%)
Diseases type			
Acute leukemia	44 (38%)	5 (28%)	39 (39%)
Lymphoma	46 (39%)	6 (33%)	40 (40%)
MDS/MPD	27 (23%)	7 (39%)	20 (20%)
Disease risk			
High	91 (78%)	15 (83%)	76 (77%)
Low	26 (22%)	3 (17%)	23 (23%)
No. of prior chemotherapy regimens			
≥2	77 (66%)	6 (33%)	71 (72%)
<2	40 (34%)	12 (67%)	28 (28%)
Donor			
Unrelated	32 (27%)	2 (11%)	30 (30%)
Related	85 (73%)	16 (89%)	69 (70%)
HLA			
Match	90 (77%)	15 (83%)	75 (76%)
Mismatch	27 (23%)	3 (17%)	24 (24%)
Stem cell source			
G-PBMC	81 (69%)	13 (72%)	68 (69%)
Bone marrow	36 (31%)	5 (28%)	31 (31%)
Conditioning regimen			
2CdA/Bu	24 (21%)	4 (22%)	20 (20%)
2CdA/Bu/ATG	18 (15%)	4 (22%)	14 (14%)
2CdA/Bu/TBI	11 (9%)	1 (6%)	10 (10%)
Flu/Bu	38 (32%)	8 (44%)	30 (30%)
Flu/Bu/ATG	11 (9%)	1 (6%)	10 (10%)
Flu/Bu/ATG/TBI	2 (2%)	0 (0%)	2 (2%)
Flu/Bu/TBI	13 (11%)	0 (0%)	13 (13%)

Acute leukemia (n=44): acute myelogenous leukemia (AML; n=23), AML evolving from a myelodysplastic syndrome (n=16), and acute lymphoblastic leukemia (ALL; n=5); Lymphoma (n=46): malignant lymphoma (44), chronic lymphocytic leukemia (CLL; n=1) and multiple myeloma (MM; n=1); MDS/MPD (n=27): MDS n=16 and MPD including chronic myelogenous leukemia (n=9) and atypical CML (n=2); G-PBMC indicates granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells; 2CdA, cladribine; Bu, busulfan; Flu, fludarabine; ATG, anti-human T-lymphocyte immunoglobulin; TBI, total-body irradiation.

2-4 Gy TBI (n = 26) or antihuman T-lymphocyte immunoglobulin (Fresenius Biotech GmbH, Germany) (ATG; 5-10 mg/kg, n = 31).

In Japan, only bone marrow is permitted as a stem cell source in transplantation from an unrelated healthy volunteer donor. In the setting of nonmyeloablative SCT from an unrelated donor, the sustained engraftment rate has been reported to be lower for recipients of bone marrow than for those given granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells (G-PBMC) [14]. Therefore, low-dose TBI was also added to the conditioning regimen in 25 of the 32 patients who underwent reduced intensity stem cell transplantation (RIST) from an unrelated bone marrow donor to facilitate engraftment. Recipients of HLA-mismatched grafts tended to receive ATG-containing conditioning regimens (20 of the 27 recipients of HLA-mismatched grafts [74%] versus 11 of the 90 recipients of HLA-matched grafts

[12%]). Prophylaxis for GVHD consisted of cyclosporin (CsA) alone ($n = 55$), Cyclosporin with short-term methotrexate (sMTX) ($n = 38$), tacrolimus alone ($n = 13$), or tacrolimus with sMTX ($n = 11$).

In 81 of the 117 patients, the source of stem cells was G-PBMC from a related donor, which contained a mean of 3.3×10^6 CD34⁺ cells/kg (range: 1.5 - 7.0×10^6 CD34⁺ cells/kg) and 8.7×10^7 CD3⁺ cells/kg (range: 6.4 - 86.1×10^7 CD3⁺ cells/kg). The other 36 patients received related ($n = 4$) or unrelated ($n = 32$) bone marrow, which contained a mean of 2.9×10^8 total nucleated cells (TNC)/kg (range: 0.97 - 6.53×10^8 TNC/kg).

A total of 9 patients received donor lymphocyte infusion (DLI), mainly after day 90, and all of them received DLI for relapse of disease. There was no patient who received DLI for low donor T cell chimerism.

Informed consent was obtained according to the Declaration of Helsinki.

Definitions

Graft failure was defined as (1) failure of absolute neutrophil count (ANC) to surpass $500/\text{mm}^3$ at day 30 after HSCT or (2) decrease in ANC $<100/\text{mm}^3$ at 3 determinations after the initial engraftment or (3) absence of donor T cells ($<5\%$) before relapse, disease progression, second HSCT, or death. The diagnosis and clinical grading of acute and chronic GVHD (aGVHD, cGVHD) were performed according to established criteria [15-17]. Complete remission (CR) was defined as according to the International Workshop Criteria in AML [18] and lymphoma [19] patients. Low disease risk was defined as AML or ALL in first CR, MDS-refractory anemia, and CML in first chronic phase. All other diagnoses were classified as high risk.

Chimerism Analysis

We assessed donor-recipient chimerism by the polymerase chain reaction (PCR)-based amplification of a polymorphic short tandem repeat region. Chimerism was evaluated using peripheral blood samples on days 30, 60, and 90 after transplantation. Samples were separated using Ficoll-hypaque into mononuclear cells and a precipitate that included red blood cells and granulocytes. Mononuclear cells were further separated into CD3-positive and -negative fractions with immunomagnetic beads (CD3 Magnetic Particles-DM, BD Pharmingen, San Diego, CA). Granulocytes were collected by lysing red blood cells in the precipitate. Briefly, DNA was extracted from selected cells using QIAamp DNA Mini Kit (QIAGEN, Hilden, Germany). Multiplex PCR was performed using primer sets (AmpFISTR Identifier Kit, Applied Biosystems, Foster City, CA). Five-color fluorescence detection was performed on an ABI 3100-Avant Genetic

Analyzer (Applied Biosystems). For each STR allele, the area under the curve for the corresponding signal was automatically processed using GeneScan 3.7 software (Applied Biosystems). The percentage of donor cells was calculated as (area signal donor)/(area signal donor + area signal recipient). The range of the error of chimerism was regarded as 5% at our laboratory (Heike et al., unpublished data).

Statistical Analysis

The chi-square test, Fisher's exact test, and Pearson correlation coefficients were used to evaluate the association of percent donor chimerism with various clinical factors such as patient age at the time of RIST (with 55 years as a cutoff), disease type (acute leukemia, MDS/myeloproliferative disease [MPD], lymphoma), disease risk (high, low), stem cell source (G-PBMC, bone marrow), serologic HLA matching (match, mismatch), and conditioning with TBI (yes, no) or ATG (yes, no).

Overall survival (OS) was defined as the time between stem cell infusion to death from any cause. Event-free survival (EFS) was defined as the time from stem cell infusion to graft failure, PD, or nonrelapse mortality (NRM), whichever occurred earlier. OS and EFS were estimated by the Kaplan-Meier method [20]. The log-rank test and the generalized Wilcoxon test were used to compare the probabilities of survival after HSCT over time across patient subgroups. Multiple Cox regression models were used for multivariate risk factor analysis for OS and EFS. Clinical factors evaluated in the OS and EFS analyses were donor T cell chimerism at day 30 (with 60% as a cutoff), patient age at the time of RIST, disease type, disease risk, stem cell source, HLA matching, and conditioning. Logistic regression models were used for multivariate risk factor analysis for low donor T cell chimerism ($<60\%$) at day 30. Clinical factors evaluated for the risk of low donor T cell chimerism at day 30 were number of prior chemotherapy regimens (≥ 2 , <2) and donor type in addition to the variables mentioned above. We considered 2-sided P -values of $<.05$ to be statistically significant. Statistical analyses were performed with SAS version 8.2 (SAS Inc., Cary, NC).

RESULTS

Kinetics of Chimerism

Whereas 43% of the patients retained mixed donor chimerism ($<90\%$ donor) in the T cell fraction, 92% achieved complete chimerism ($\geq 90\%$) in the granulocyte fraction at day 30 after RIST (Figure 1). In the peripheral blood mononuclear cell (PBMC) fraction, 72% of the patients achieved complete chimerism




Figure 1. Distribution of chimerism status at day 30 after RIST.

(≥90%). The percent donor-chimerism was significantly higher in granulocyte than T cell fraction throughout the entire course, and the median (mean) values were, respectively, 100% (96%) versus 95% (83%), 100% (98%) versus 100% (89%), and 100% (98%) versus 100% (91%) at days 30, 60, and 90, respectively after RIST (Figure 2).

In univariate and multivariate analyses (Table 2), having received <2 types of chemotherapy regimens before RIST was the only factor that was significantly associated with low donor T cell chimerism (<60%) at day 30 (hazard ratio [HR]: 6.1; 95% confidence interval [CI], 2.1-18.4; $P < .01$). Non-TBI regimens and related donor also tended to be associated with lower donor T cell chimerism.

Graft Composition and Donor Chimerism

By examining the impact of graft composition of G-PBMC on donor chimerism, we found that increases in TNC and CD3+ T cells contents paralleled the increase in donor T cell chimerism at day 30 ($P < .03$ and $P < .05$, respectively). The same relationship was observed between CD34+ cell contents and granulocyte chimerism ($P = .06$). In patients who received bone marrow, a higher number of TNC infused was associated with a higher level of donor T cell chimerism at day 30 ($P < .01$).




Figure 2. Kinetics of chimerism status after RIST (mean percentages of donor chimerism levels). Percent donor cell chimerism was significantly higher in granulocyte than T cell fraction throughout the entire course, and the mean values were, respectively, 96% versus 83%, 98% versus 89%, and 98% versus 91% at days 30, 60, and 90 after RIST.

Table 2. Factors affecting low donor T cell chimerism (<60%) at day 30

Characteristics	Univariate analysis		Multivariate analysis	
	Odds ratio (95% CI)	P	Odds ratio (95% CI)	P
Patient age, years				
<55	1			
≥55	2.04 (0.71 - 5.87)	0.19		
Disease type				
Lymphoma	1			
MDS/MPD	2.33 (0.69 - 7.87)	0.17		
Acute leukemia	0.86 (0.24 - 3.03)	0.81		
Disease risk				
Low	1			
High	1.51 (0.40 - 5.69)	0.54		
No. of prior chemotherapy regimens				
≥2	1		1	
<2	5.07 (1.73-14.83)	<0.01	6.08 (2.01-18.41)	<0.01
Stem cell source				
G-PBMC	1			
Bone marrow	0.84 (0.28 - 2.57)	0.77		
Donor				
Unrelated	1		1	
Related	3.48 (0.75-16.08)	0.11	4.21 (0.86-20.49)	0.08
HLA				
Match	1			
Mismatch	0.63 (0.17 - 2.34)	0.49		
TBI				
No	1		1	
Yes	0.17 (0.02 - 1.38)	0.10	0.13 (0.02-1.05)	0.06
ATG				
No	1			
Yes	1.08 (0.35 - 3.32)	0.89		

Association between Donor T Cell Chimerism at Day 30 and RIST Outcome

Graft failure

The median (mean) percentage of donor T cell chimerism at day 30 was 9% (18%) (0%-63%) in 5 patients who experienced graft failure, which was significantly lower than those in the other patients (97% [86%], 15%-100%, $P < .01$), as shown in Figure 3. Day 30 T cell chimerism below 60% was associated with a significantly increased risk of graft failure (Table 3). Among the 5 patients who experienced graft failure, 4 had achieved complete donor chimerism at day 30 when evaluated in the granulocyte fraction.

Whereas 4 of the 5 patients (80%) who experienced graft failure received HLA-mismatched grafts, 23 of the 112 patients (21%) who did not experience graft failure received HLA-mismatched grafts ($P = .01$). In a multivariate analysis, however, neither day 30 T cell chimerism below 60% nor HLA mismatch was associated with an increased risk of graft failure. Among 18 patients with <60% donor T cell chimerism at day 30, HLA mismatch was significantly associated with an increased risk of grafts failure (3 of 3 who received HLA-mismatched graft versus 1 of 15 who received HLA-matched grafts, $P = .005$). In contrast, HLA mismatch was not associated with an increased risk of graft failure in 99 patients with 60% or more donor T cell chimerism at day 30 (1 of 24




Figure 3. Donor T cell chimerism levels at day 30 in patients with or without subsequent graft failure. Five of the 117 patients (4%) who experienced graft failure had a significantly lower donor T cell chimerism level than the other engrafted patients ($n = 112$) (donor T cell chimerism, median 9% [range: 0%-63%] versus 97% [range: 15%-100%], respectively) ($p < .01$). Horizontal lines, median; boxes, 25-75 percentile; vertical lines, 10-90 percentile; circles, individual data outside the 10-90 percentile.

who received HLA-mismatched grafts versus 0 of 75 who received HLA-matched grafts, $P = .24$).

GVHD

Grade II-IV aGVHD occurred in 54 patients (46%), and cGVHD occurred in 63 patients (64%). No correlation was found between the kinetics of T

Table 3. Association between donor T-cell chimerism at day 30 and clinical outcome

Outcome	Total ($n = 117$)	T-cell chimerism at day 30		<i>P</i>
		<60% ($n = 18$)	$\geq 60\%$ ($n = 99$)	
Graft failure				
No	112 (96%)	14 (78%)	98 (99%)	<0.01
Yes	5 (4%)	4 (22%)	1 (1%)	
Acute GVHD				
0-I	64 (55%)	11 (61%)	53 (54%)	0.55
II-IV	53 (45%)	7 (39%)	46 (46%)	
Chronic GVHD*				
No	36 (36%)	7 (50%)	29 (34%)	0.25
Yes	63 (64%)	7 (50%)	56 (66%)	
NRM (at 1 year)	11.0%	11.1%	10.9%	0.26
PD (at 1 year)	27.3%	22.6%	28.1%	0.45
OS (at 1 year)	78.0%	65.7%	80.3%	0.02
EFS (at 1 year)	61.8%	55.6%	62.8%	0.02

GVHD indicates graft-versus-host disease; NRM, non-relapse mortality; PD, relapse or progressive disease; OS, overall survival; EFS, event-free survival;

*Proportion of patients with chronic GVHD was assessed among 99 evaluable patients.

cell chimerism and the occurrence of aGVHD or cGVHD, as shown in Table 3.

NRM and PD

Nineteen patients experienced NRM, with a 1-year probability of 11% (Table 3). No correlation was found between T cell chimerism at day 30 and the incidence of NRM.

PD was observed in 39 patients, with a 1-year probability of 27% (Table 3). No correlation was found between T cell chimerism at day 30 and the incidence of PD.

Cause of death

Among the 18 patients who had <60% donor T cell chimerism at day 30, 7 (39%) died of PD and 4 (22%) died of NRM, including bacteria sepsis ($n = 2$), pneumonitis ($n = 1$), and secondary carcinoma ($n = 1$). In contrast, among the remaining 99 patients who achieved 60% or more donor T cell chimerism, 21 (21%) died of PD and 15 (15%) died of NRM, including pneumonitis ($n = 8$), sepsis ($n = 3$), hemorrhage ($n = 1$), GVHD ($n = 1$), cerebral infarction ($n = 1$), and unknown cause ($n = 1$).

OS and EFS

Seventy patients (60%) are currently alive at a median follow-up of 1040 days after RIST (range: 153-2535). The 1-year probabilities of OS and EFS among all of the patients were 78% and 62%, respectively. As shown in Figure 4, OS was significantly better in patients who achieved 60% or more donor T cell chimerism at day 30 than in those who did not ($P = .02$). In a Cox proportional hazard model, low T cell donor chimerism (<60%) at day 30 was associated with poor OS (HR: 2.2; 95% CI, 1.1-4.5; $P = .02$) and EFS (HR: 2.0; 95% CI, 1.1-3.8; $P = .02$) adjusted for other significant prognostic factors (Table 4). In addition, high-risk disease and patient age (≥ 55 years) were associated with an increased risk of poor EFS (HR: 2.4; 95% CI, 1.2-5.0; $P = .02$, HR: 1.8; 95% CI, 1.1-3.0; $P = .03$, respectively) (Table 4).




Figure 4. OS stratified according to donor T cell chimerism at day 30. OS was significantly better in patients who achieved 60% or more donor T cell chimerism at day 30 than in those who did not ($P = .02$).

Table 4. Multivariate analysis: factors associated with clinical outcome

Outcome	Variable	Harzard ratio	95% CI	P
OS	Donor T-cell chimerism at day 30	1		
	≥60%	2.25	1.13-4.47	0.02
	<60%			
EFS	Donor T-cell chimerism at day 30	1		
	≥60%	2.05	1.10-3.81	0.02
	<60%			
	Patients age, years	1		
	<55	1.80	1.07-3.04	0.03
	≥55			
Disease risk	Low	1		
	High	2.44	1.19-5.01	0.02

Clinical factors evaluated in the OS and EFS analyses were donor T-cell chimerism at day 30 (with 60% as a cutoff), patient age at the time of RIST, disease type, disease risk, stem cell source, HLA matching and conditioning.

DISCUSSION

In this retrospective study of RIST with Bu, we showed that 43% of the patients retained mixed donor T cell chimerism (<90%), whereas 92% achieved complete chimerism in the granulocyte fraction, which was consistent with previously published observational studies in RIST [4,10,11,13,21]. Furthermore, we showed that low donor T cell chimerism of <60% at day 30 predicted poor OS and EFS, which suggests that the kinetics of T cell chimerism are important after Bu-containing RIST.

Consistent with other reports, we found that the induction of complete chimerism in T cell fraction after a Bu-containing regimen was rather slow, and granulocyte engraftment was earlier than T cell engraftment compared to patients who received RIC regimens containing a combination of Flu and Mel [10]. When the combination of Cy and Flu was used for RIST conditioning, full donor chimerism was achieved earlier in T cells than in myelogenous cells [1,22]. Interestingly, when alemtuzumab was used in a RIC regimen, 58% retained mixed donor chimerism at day 90 after RIC [13]. This may be because of the fact that alemtuzumab remained in the peripheral circulation long after RIST, which suppressed not only host but also donor lymphocytes. Based on these reports, we suspected that a Cy-containing regimen suppresses host granulocytes less intensely than a Bu-containing regimen, whereas a Mel-containing regimen suppresses host lymphocytes more intensely than a Bu-containing regimen.

The only significant variable associated with a lower level of donor T cell chimerism at day 30 was having received <2 regimens of chemotherapy pretransplant in our results. This result was consistent with previous reports [4,10]. When a patient is treated

with RIST, such as our low-dose Bu-containing regimen, prior chemotherapy may facilitate the achievement of higher levels of donor T cell chimerism by decreasing the recipient immunocompetence.

In previous reports there has been some controversy regarding whether there are any differences in the levels of donor T cell chimerism after RIST with or without low-dose TBI [11,13]. In our study with Bu-containing regimens, regimens that included additional low-dose TBI tended to offer higher donor T cell chimerism in a multivariate analysis. However, there was no correlation between ATG-conditioning regimens and donor T cell chimerism at day 30, which was consistent with other regimens [13]. This might be because of the lower dose of ATG (Fresenius, 5-10 mg/kg) in our regimens compared to other studies that utilized the same ATG preparation (Fresenius, 40-90 mg/kg) [23,24]. Alternatively, this might be simply because of the small number of patients who received ATG in our study.

In previous reports, recipients of G-PBMC after RIST showed higher percentages of donor T cell chimerism than those who received bone marrow [4,25], which was not confirmed in our study. With regard to regimens that include Bu, no previous large-scale study has analyzed the correlation between the type of stem cell source and T cell engraftment. When low-dose Bu is contained in the RIC regimen, the stem cell source may no longer influence the level of T cell chimerism. Alternatively, this may be because of the fact that most of the bone marrow recipients in our study also received an additional 2-4 Gy TBI. There was a trend toward a decreased risk of low donor T cell chimerism in recipients of unrelated grafts, although the difference was not significant. We speculate that a lower probability of low donor T cell chimerism might be because of the addition of low dose TBI for patients who underwent unrelated HSCT.

Patients who received G-PBMC showed an increase in TNC and CD3⁺ T cells that paralleled an increase in donor T cell chimerism at day 30 after RIST in our study. The same relationship was observed between CD34⁺ cell contents and granulocyte chimerism. Baron et al. [26] reported that higher numbers of donor T cells and CD34⁺ progenitor cells in the grafts were associated with higher levels of day 28 donor T cell chimerism. Similarly, Carvallo et al. [22] reported that higher levels of CD34⁺ progenitor cells in the grafts were associated with higher levels of donor myeloid chimerism early after RIST.

In this study, donor T cell chimerism levels of below 60% early after RIST were significantly associated with an increased risk of graft failure. It has been reported that patients with <50% donor T cell chimerism early after nonmyeloablative HSCT were more likely to have graft failure than those with more than

50% donor T cell chimerism [4]. After Bu-containing RIC, Mattsson et al. [21] reported that 2 of the 8 patients who had >50% recipient T cells on day 28 had graft failure or rejection, whereas this was not seen in any of the 22 patients with <50% recipient T cells. Lower donor natural killer NK-cell chimerism after Bu-containing RIST was associated with an increased risk of graft failure [4,27]. Although significant associations of low donor T cell chimerism and HLA mismatch with graft failure disappeared in our multivariate model, our data suggested that HLA mismatch was an important predictor of graft failure only in patients with <60% donor T cell chimerism at day 30. The current study demonstrated that patients at high risk of graft failure could be identified by chimerism analysis at day 30 in T cell fractions, but not in granulocyte fractions, and that chimerism analysis at day 30 after Bu-containing RIST may allow early interventions aimed at reversing graft failure.

Our results suggest that low donor T cell chimerism of <60% at day 30 may predict a poor outcome, although levels of donor T cell chimerism were not associated with NRM PD. In our study, the levels of donor T cell chimerism were not associated with aGVHD or cGVHD, although some reports have stated that donor T cell chimerism was associated with the risk of GVHD [1,4,13,19,28]. It is still controversial whether or not achievement of complete donor T cell chimerism is needed to improve OS and reduce the relapse risk in patients who undergo RIST. Baron et al. [9] suggested that the assessment of donor chimerism levels helps to identify patients who are at higher risk of relapse after nonmyeloablative HSCT. High donor chimerism levels among immune competent cells including T cells and NK cells might be a surrogate for a high graft-versus-tumor effect, and a fractionated chimerism analysis may be useful for detecting and quantifying minimal residual disease after RIST. In a small case series of Bu-containing RIST, mixed donor chimerism was associated with an increased risk of relapse and a worse prognosis [12,29]. In contrast, among patients who underwent RIST that contained Flu, Bu, and alemtuzumab, those who showed mixed donor chimerism beyond day 100 were associated with an improved OS and a lower incidence of GVHD and NRM, without any effect on the relapse risk [13]. Further studies are needed to determine whether the achievement of complete chimerism after RIST is beneficial with less risk of PD and/or more risk of NRM.

In conclusion, within the limitations of a retrospective study, we found that the percentage of donor chimerism was significantly higher in granulocyte than T cell fraction throughout the entire course after Bu-containing RIST. Low donor T cell chimerism of <60% at day 30 may predict a poor outcome, and

a prospective study to examine the value of early intervention based on chimerism data is warranted.

ACKNOWLEDGMENTS

Financial disclosure: This work was supported in part by grants from the Ministry of Health, Labor and Welfare, Japan, and grants from the Advanced Clinical Research Organization.

This paper was presented in part as a poster presentation at the 49th Annual Meeting of the American Society of Hematology, Atlanta, GA, December 2007. We thank the medical, nursing, data processing and laboratory staffs at the National Cancer Center Hospital for their important contributions to this study through dedicated care of the patients.

REFERENCES

- Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. *Blood*. 1999;94:3234-3241.
- Shimoni A, Hardan I, Shem-Tov N, et al. Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan. *Leukemia*. 2007;21:2109-2116.
- Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. *Blood*. 1998;91:756-763.
- Baron F, Baker JE, Storb R, et al. Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. *Blood*. 2004;104:2254-2262.
- Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. *Blood*. 2000;96:2419-2425.
- McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. *Blood*. 2001;97:3390-3400.
- Barrett AJ, Savani BN. Stem cell transplantation with reduced-intensity conditioning regimens: a review of ten years experience with new transplant concepts and new therapeutic agents. *Leukemia*. 2006;20:1661-1672.
- Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: recommendations from a workshop at the 2001 Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. *Biol Blood Marrow Transplant*. 2001;7:473-485.
- Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. *Leukemia*. 2006;20:1690-1700.
- Valcárcel D, Martino R, Caballero D, et al. Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. *Bone Marrow Transplant*. 2003;31:387-392.

11. Miura Y, Tanaka J, Toubai T, et al. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and nonmyeloablative stem cell transplantation. *Bone Marrow Transplant.* 2006;37:837-843.
12. Mohty M, Avinens O, Faucher C, Viens P, Blaise D, Eliaou JF. Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. *Haematologica.* 2007;92:1004-1006.
13. Lim ZY, Pearce L, Ho AY, et al. Delayed attainment of full donor chimerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. *Br J Haematol.* 2007;138:517-526.
14. Maris MB, Niederwiser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. *Blood.* 2003;102:2021-2030.
15. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. *Transplantation.* 1974;18:295-304.
16. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. *Bone Marrow Transplant.* 1995;15:825-828.
17. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. *Semin Hematol.* 1991;28:250-259.
18. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendation of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. *J Clin Oncol.* 2003;21:4642-4649.
19. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. *J Clin Oncol.* 1999;17:1244-1253.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc.* 1958;53:457-481.
21. Mattsson J, Uzunel M, Brune M, et al. Mixed chimerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. *Br J Haematol.* 2001;115:935-944.
22. Carvallo C, Geller N, Kurlander R, et al. Prior chemotherapy and allograft CD34+ dose impact donor engraftment following nonmyeloablative allogeneic stem cell transplantation in patients with solid tumors. *Blood.* 2004;103:1560-1563.
23. Zander AR, Kroger N, Schleuning M, et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). *Bone Marrow Transplant.* 2003;32:355-361.
24. Basara N, Baurmann H, Kolbe K, et al. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. *Bone Marrow Transplant.* 2005;35:1011-1018.
25. Dey BR, Shaffer J, Yee AJ, et al. Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen. *Bone Marrow Transplant.* 2007;40:19-27.
26. Baron F, Maris MB, Storer BE, et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. *Leukemia.* 2005;19:822-828.
27. Bronhauser M, Thiede C, Platzbecker U, et al. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donor in 42 patients. *Clin Cancer Res.* 2001;7:2254-2262.
28. Balon J, Haaburda K, Bieniaszewska M, et al. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease. *Bone Marrow Transplant.* 2005;35:1083-1088.
29. Pérez-Simón JA, Caballero D, Diez-Campelo M, et al. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation. *Leukemia.* 2002;115:935-944.

Hyperglycemia During the Neutropenic Period Is Associated With a Poor Outcome in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

Shigeo Fuji,¹ Sung-Won Kim,¹ Shin-ichiro Mori,¹ Takahiro Fukuda,¹ Shigemi Kamiya,² Satoshi Yamasaki,¹ Yuriko Morita-Hoshi,¹ Fusako Ohara-Waki,¹ Osamu Honda,³ Setsuko Kuwahara,² Ryuji Tanosaki,¹ Yuji Heike,¹ Kensei Tobinai,¹ and Yoichi Takaue^{1,4}

Background. Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) frequently require support with parenteral nutrition and immunosuppressive drugs, which introduce the risk of hyperglycemia. Van den Berghe et al. showed that the strict glucose control improved the outcome of patients treated in the intensive care unit, and this point was evaluated in this study in a HSCT setting.

Methods. A cohort of 112 consecutive adult patients treated by myeloablative allogeneic HSCT between January 2002 and June 2006 was reviewed retrospectively. Twenty-one patients were excluded due to graft failure, preexisting infectious diseases, preexisting neutropenia or previous allogeneic HSCT. The remaining 91 patients were categorized according to mean fasting blood glucose (BG) level in the neutropenic period after conditioning: normoglycemia (BG <110 mg/dL, n=28), mild hyperglycemia (110 to 150 mg/dL, n=49), and moderate/severe (>150 mg/dL, n=14). The primary endpoint was the occurrence of febrile neutropenia (FN) and documented infection during neutropenia, and the secondary endpoints included organ dysfunction according to the definition used by van den Berghe, acute graft-versus-host disease (GVHD), overall survival, and nonrelapse mortality (NRM).

Results. Although the incidence of FN or documented infections was similar between the three groups, hyperglycemia was significantly associated with an increased risk of organ dysfunction, grade II–IV acute GVHD, and NRM.

Conclusions. While the results suggested an association between the degree of hyperglycemia during neutropenia and an increased risk of posttransplant complications and NRM, the possibility that intensive glucose control improves the outcome after HSCT can only be confirmed in a prospective randomized trial.

Keywords: Allogeneic transplantation, Hyperglycemia, Nonrelapse mortality, Acute graft-versus-host disease.

(*Transplantation* 2007;84: 814–820)

Van den Berghe et al. showed with patients nursed in the intensive care unit (ICU) that the rigid control of hyperglycemia with intensive insulin therapy to keep the blood glucose level at 80–110 mg/dL reduced morbidity, including infec-

tions, and mortality compared to patients who received standard care maneuvers that maintained the level at <200 mg/dL (1–3). Although these results have been confirmed in several subsequent studies (4–7), the precise mechanism that underlies this association is unclear. In animal models, it has been shown that insulin itself has a direct inhibitory effect on the inflammation process (8, 9). However in human studies, it has been suggested that these benefits could be directly attributed to intense glucose control rather than to any pharmacological activity of administered insulin per se (3, 4).

Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) suffer from serious complications including infection, graft-versus-host disease (GVHD) and organ dysfunction. They are also at higher risk of hyperglycemia due to the use of steroids for the treatment of graft-versus-host disease (GVHD), prolonged total parenteral nutrition (TPN), immunosuppressive drugs, and infectious complications (10, 11). This makes them susceptible to numerous serious complications, including multiple organ failure (12–14). In this study, we evaluated whether hyperglycemia during the cytopenic pe-

Supported in part by grants from the Ministry of Health, Labor and Welfare, Japan.

This paper was presented in part as a poster presentation at the tandem Meeting of ASBMT and IBMTR, Keystone, Colorado, February 2007.

¹ Department of Hematology and Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.

² Division of Nutritional Management, National Cancer Center Hospital, Tokyo, Japan.

³ Tokyo Anesthesiology Group, Tokyo, Japan.

⁴ Address correspondence to: Yoichi Takaue, M.D., Department of Hematology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-Ku, Tokyo 104-0045, Japan.

E-mail: ytakaue@ncc.go.jp

Received 12 June 2007. Revision requested 10 July 2007.

Accepted 18 July 2007.

Copyright © 2007 by Lippincott Williams & Wilkins

ISSN 0041-1337/07/8407-814

DOI: 10.1097/01.tp.0000282790.66889.a5